Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday

Contineum Therapeutics (NASDAQ:CTNM) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Contineum Therapeutics Trading Down 0.5%

CTNM opened at $3.81 on Wednesday. The stock has a fifty day moving average price of $5.50 and a 200 day moving average price of $10.20. Contineum Therapeutics has a 1 year low of $3.64 and a 1 year high of $22.00. The stock has a market cap of $98.57 million and a price-to-earnings ratio of -0.78.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Robert W. Baird reduced their price target on Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Contineum Therapeutics in a research report on Friday, March 7th. Finally, Jones Trading started coverage on shares of Contineum Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $23.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $23.75.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).